OISTV

Watch presentations from innovators/entrepreneurs, surgeons, academia, venture capitalists, industry leaders and private & public companies.


Tom Frinzi of WaveTec Vision Systems

WaveTec Vision Systems

Tim Willis of TearScience

TearScience

Barry Cheskin of PowerVision

PowerVision

Quinton Oswald of Neurotech

Neurotech

Robert Butchofsky of Mati Therapeutics

Mati Therapeutics

Ronen Castro of IOPtima

IOPtima

Max Ostermeier of Implandata Ophthalmic Products GmbH

Implandata Ophthalmic Products GmbH

John Maroney of ForSight VISION5

ForSight VISION5

David Muller of Avedro

Avedro

Russell Trenary of InnFocus

InnFocus

Dan Myers of Alimera Sciences

Alimera Sciences

Franz Obermayr of Panoptes

Panoptes Developing Inhibitor For Local Treatments In Ocular Disease

Shelly Boyd of Translatum Medicus

Translatum Medicus Developing Option To Treat Dry AMD

Charlie McDermott of Kala Pharmaceuticals

Kala Pharmaceuticals Offers Glimpse Into Preclinical Pipeline

John Freshly of ONL

ONL Therapeutics Develops Novel Mechanism To Attack Fas Receptor Apoptosis

Vicente Anido of Aerie Pharaceuticals

Aerie Pharmaceuticals With Two ROCK Inhibitors In Development

Henry Hsu of Allysta

Allysta Pharmaceuticals Developing Multi-Kinase Inhibitor To Treat Glaucoma

Amarpreet Sawhney of Ocular Therapeutix

Ocular Therapeutix

Michael O'Rourke of GrayBug

GrayBug With Preclinical Work On Microparticle Anti-VEGF Compound GB-102

Ed Timm of Mobius Therapeutics

Mobius Therapeutics Investigates Extending Mitosol Platform

Bernhard Gunther of Novaliq

Novaliq GmbH Using Semifluorinated Alkanes To Improve Solubility Of Topical Agents

Paul Rubin of Xoma

Monoclonal Antibody Company XOMA Corp. Shares New Strategy

David R. Guyer of Ophthotech

Ophthotech Shares Late-Stage Progress of Fovista

Vicken Karageozian of Allegro

Allegro Gives Phase II News on Luminate

Thomas W. Chalberg of Avalanche

Avalanche Biotechnologies Gives Ocular BioFactory Tour

Jesper J. Lange of MC2

MC2 Biotek Group Offers Insights on PAD

How Alcon and Google Could Change The Contact Lens

How Alcon and Google Could Change The Contact Lens

Studies Underway For Sustained-Release Injectable Anti-VEGFs For Posterior Diseases

Studies Underway For Sustained-Release Injectable Anti-VEGFs For Posterior Diseases

CLASS Procedure May Be Safe Alternative To Trabeculectomy

CLASS Procedure May Be Safe Alternative To Trabeculectomy

Glaucoma Products In The Pipeline For Aerie

Glaucoma Products In The Pipeline For Aerie

Noel Alpins @ OIS

CorT Measures Total Corneal Power

Eliot J. Lazar MD

Innovation Summit Brings Industry, Investors, Ophthalmologists Together

Nanotechnology Company Developing Better Drug Delivery To The Eye

Nanotechnology Company Developing Better Drug Delivery To The Eye

Robert Butchofsky @ OIS

Sustained Drug Delivery Platform May Eliminate Daily Administration

Kala Highlights Investigational KPI-121

Kala Highlights Investigational KPI-121

Gregory Hageman @ OIS

Gene Therapy On The Tipping Point

Ophthalmology, Technology Intersect At OIS

Ophthalmology, Technology Intersect At OIS

Allegro Begins Phase 2 Study For Treatment Of DME

Allegro Begins Phase 2 Study For Treatment Of DME

Amar Sawhney update on Ocular Therapeutix

Ocular Therapeutix Update by CEO Amar Sawhney, PhD

Gilbert Kliman discusses topics at OIS@AAO

Gilbert Kliman Gives Overview of Topics Being Discussed at OIS@AAO

Harvey Fishman Overview of AppVisit

AppVisit Overview by Co-Founder Harvey Fishman, MD, PhD

James Mazzo on Industry Collaboration

What Is Actually Happening In Industry Consolidation?

Noel Alpins Update for Assort

Assort Update by CEO Noel Alpins, MD, FACS

Allegro Ophthalmics Update by Co-Founder Vicken Karageozian, MD

Allegro Ophthalmics Update by Co-Founder Vicken Karageozian, MD

Robert Dempsey gives Update for Shire Ophthalmics

Shire Ophthalmics Update by VP & Biz Unit Head Robert Dempsey

Ronen Castro Update of IOptima

IOPtima Update by CEO Ronen Castro

Aerie Pharmaceuticals Update by CEO Vicente Anido Jr., PhD

Aerie Pharmaceuticals Update by CEO Vicente Anido Jr., PhD

Tom Brogan of Vestrum Health

Vestrum Health Update by Chairman of the Board Tom Brogan

Cross Linking Panel Discussion

Cross Linking – Panel Discussion

Dry Eye Panel Discussion

Dry Eye Challenges & Opportunities

Page 1 of 512345
Share with your friends










Submit